Second-generation CML drugs show promise as frontline therapy

Dec 08, 2008

Two drugs approved as fallback therapy for chronic myelogenous leukemia (CML) appear to outperform historical benchmarks of the frontline medication when used as a first treatment in separate clinical trials, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 50th Annual Meeting of the American Hematological Society.

Frontline therapy for CML remains imatinib, a Novartis drug known as Gleevec® and a major success story in targeted cancer treatment that has increased the five-year survival rate for the disease from 50 percent to 90 percent of patients.

"We are seeing more patients achieve complete cytogenetic responses faster with either drug than we did during clinical trials with imatinib," said Jorge Cortes, M.D., professor in M. D. Anderson's Leukemia Department and leader of both studies. "These are early but encouraging results."

Complete cytogenetic response is the absence of the defective chromosome that causes the disease. Cortes and colleagues compare current clinical trial results to M. D. Anderson's extensive historical results from earlier trials of imatinib.

Researchers are comparing nilotinib, a Novartis drug known as Tasigna®, and dasatinib, a Bristol-Myers Squibb drug known as Sprycel®, to imatinib. Both are approved by the U.S. Food and Drug Administration for patients who can't tolerate imatinib or whose CML resists the drug.

The nilotinib trial has enrolled 49 patients with previously untreated early stage CML, and some with second stage disease. The 400mg twice daily dose led to complete cytogenetic response in nearly all patients as early as three months into the trial.

Overall, 44 of 46 (96 percent) evaluable patients have achieved a complete cytogenetic response at some point during the trial. At one year, 52 percent achieved a major molecular response, an even more stringent measure of disease remission.

The dasatinib trial has enrolled 50 patients with previously untreated early stage CML taking either 50 mg twice daily or 100 mg once a day. Overall, 44 of 45 patients (98 percent) have achieved complete cytogenetic response at some point during the trial. At one year, 34 percent have achieved major molecular response.

While both dasatinib and nilotinib have so far outperformed a 400mg daily dose of imatinib at all times, longer-term results are converging with those seen with an 800 mg daily dose of imatinib.

Both clinical trials continue to enroll patients. Side effects are being closely monitored and some patients in each trial had their doses reduced or treatment temporarily interrupted to deal with toxicities. "Side effects so far are manageable and comparable to those seen with imatinib," Cortes said.

Imatinib targets the aberrant Bcr-Abl protein, caused by a chromosomal abnormality called the Philadelphia Chromosome, which fuels an overabundance of white blood cells and immature stem cells called blasts that crowd out red blood cells and platelets. Nilotinib and dasatinib target a greater variety of genetic variations leading to CML and often work after imatinib has failed.

The clinical trials are funded by Novartis and Bristol-Myers Squibb who provide both study medicines for off-label use.

Source: University of Texas M. D. Anderson Cancer Center

Explore further: FDA approves second vaccine against meningitis strain

add to favorites email to friend print save as pdf

Related Stories

New lab test could identify imatinib resistance

Jul 29, 2010

Scientists in Japan may have developed a way to accurately predict those patients who will resist treatment with imatinib, which is the standard of care for chronic myeloid leukemia (CML).

Recommended for you

Medical charity warns India over patent rules

Jan 21, 2015

Doctors without Borders on Wednesday warned the Indian government not to bow to US pressure to amend patent regulations that allow millions access to affordable medicines, ahead of a visit by President Barack Obama.

Why are some generic drugs getting so expensive?

Jan 21, 2015

More than eight out of every 10 prescriptions dispensed in the US is generic. This growth is due to a large number of top-selling drugs going off patent over the past decade, as well as innovations in t ...

Supreme Court sides with Teva in drug dispute

Jan 20, 2015

The Supreme Court on Tuesday sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.